Alice Han and James Kynge look ahead to Trump and Xi’s September 24 meeting in Washington, set against a busy stretch of Xi diplomacy, from the SCO summit to a first-ever trip to India, plus talk of a possible Trump-Putin-Xi trilateral in November. They dig into how trade, rare earths, and soybean purchases are shifting the leverage between the two powers, and whether the fight over AI dominance deserves more attention than the trade deficit.
Then: Ruby Wang, author of China Cure: The Rise of a Biotech, AI Medicine and Global Health Superpower, joins to unpack China’s rapid rise in pharmaceuticals — from faster, cheaper clinical trials to a wave of global licensing deals now worth tens of billions of dollars. She explains what changed since China was a clear follower in the market as recently as 2010, and what it means for U.S. pharma competitiveness.
Looking for the full version? Become a Prof G+ subscriber for unlimited, ad-free access to all our videos, including exclusive content on…
